KLOW

What it is

KLOW is BPC-157, TB-500, GHK-Cu, and KPV — the C-terminal tripeptide of alpha-MSH. It’s GLOW with one targeted addition: KPV keeps the anti-inflammatory action of the melanocortin family without the skin-darkening, making it the “calm the inflammation” piece on top of GLOW’s repair-plus-skin base. It’s marketed for gut inflammation, recovery, and skin, and the four-peptide logic is coherent: repair (BPC-157/TB-500), collagen and gene-expression remodeling (GHK-Cu), and inflammatory-signal dampening (KPV).

Dr. That’s a clinician independently arriving at the same formula.

How it works

Three of the four mechanisms are identical to GLOW: BPC-157 drives angiogenesis, TB-500 promotes cell migration via actin binding, and GHK-Cu delivers copper and signals collagen/elastin synthesis and remodeling. See GLOW for the detail.

The new piece is KPV (lysine-proline-valine, the C-terminal tripeptide of alpha-MSH). It’s a melanocortin fragment that fights inflammation by inhibiting NF-κB — the master switch cells flip to turn on inflammatory genes — and by damping MAP-kinase signaling and pro-inflammatory cytokines like TNF-α and IL-6. The distinctive part is where it acts: most anti-inflammatories try to intercept the signal at the cell surface, but KPV is carried inside the cell by the PepT1 transporter and shuts inflammation down from within. And PepT1 gets upregulated in the colon precisely when tissue is inflamed — so KPV’s delivery route actually opens wider the more inflamed the gut is (DeLauer’s apt image: “a delivery door that only opens wider when the gut needs help”). Cells lacking PepT1 show no KPV effect, confirming the transporter is the route. It does all this without needing the MC1R receptor — in MC1R-deficient mice, KPV still rescued them from colitis — which is why it’s an elegant, well-behaved anti-inflammatory: alpha-MSH’s anti-inflammatory benefit without the melanocortin/skin-darkening side effects.

The KLOW rationale, then: KPV adds an inflammation brake to a stack that otherwise pushes growth and repair — useful logic if the target is a system that’s both inflamed and trying to heal (gut, skin, recovery). The cleanest articulation of the blend’s internal logic is a sequence: KPV first calms the inflammatory fire; BPC-157 (and TB-500) then rebuild the structure — non-overlapping mechanisms, “you’re not doing the same thing twice”. KLOW packs that calm-then-rebuild logic into one vial. Note KPV’s body-composition framing too: it doesn’t burn fat or build muscle directly, but because obesity and metabolic dysfunction are partly inflammatory states, removing the inflammatory bottleneck improves the environment for both — a context-setter, not a direct lever.

What the research shows

The four-way combination itself has no published study — zero records in any model [PubMed: 0 records], which is tracked in questions.md. Since KPV is the differentiator from GLOW, here’s its evidence first, then the rest by tier.

KPV: consistent across rodent and in-vitro work:

• Oral KPV reduced DSS- and TNBS-induced colitis in mice — better weight recovery, lower inflammatory infiltrate, reduced myeloperoxidase.
• Nanoparticle-delivered KPV worked at ~12,000-fold lower doses in mouse colitis, confirming potency when delivery is solved; HA-functionalized nanoparticles outperformed plain alpha-MSH for mucosal healing.
• PepT1-dependent anti-cancer effect in a colitis-associated cancer model — KPV prevented carcinogenesis in wild-type but not PepT1-knockout mice.
• Inhibits NF-κB at nanomolar levels in human intestinal cell lines (Caco-2, HT-29); antimicrobial against S. aureus and Candida in vitro.
• The honest tier: KPV’s evidence is rodent and in-vitro, with no human trial yet — exactly where a high-potential anti-inflammatory peptide sits before clinical work. The mechanism is unusually consistent across models, which is what makes it interesting.

GHK-Cu: topical human cosmetic data (non-RCT) plus animal injectable and extensive in-vitro/mechanistic work; the McGill 28% collagen number is a press release. (Full detail in GHK-Cu.)

BPC-157: strong, consistent animal repair data; thin human data (one 12-patient case series of 544 screened, PMID 40756949; small older UC enema trials); no animal carcinogenic signal.

TB-500: animal/in-vitro; human Tβ4 trials used the pharmaceutical-grade protein, not the research fragment; 2025 STEMI RCT showed no significant overall benefit [PMID 41229390].

A current one-stop reference for three of the four: the 2026 Mendias musculoskeletal-peptide review surveys BPC-157, TB-500, and GHK-Cu together (with 7 other peptides) in one safety-and-efficacy document — handy for the GLOW base of KLOW, though it doesn’t cover KPV [REVIEW preprint, Mendias 2026, DOI 10.20944/preprints202512.1011.v3]. KPV’s own evidence sits in the colitis/NF-κB literature cited above.

Where it stands: KPV brings a clean, well-replicated anti-inflammatory mechanism that’s animal/in-vitro-grade in humans; the other three are the GLOW components. Clinic copy presents KPV as an established treatment for IBD, eczema, psoriasis, rosacea, leaky gut, and MCAS, sometimes with “improved in 3–7 days” vignettes. Those are uncontrolled observations, not efficacy data, so we don’t present them as proof. The defensible claim is the component-evidence one: a coherent gut-plus-recovery-plus-skin stack whose newest piece has a genuinely elegant, consistent mechanism and whose combination study is the open gap.

Real-world protocol

The doses and schedules below are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

The de-facto convention for KLOW, stated plainly:

• KPV standalone convention: 250 mcg – 1 mg/day, ~500 mcg/day typical (750 mcg–1 mg for more severe inflammatory/immune cases); start at ~250 mcg to assess tolerance, dose AM on an empty stomach or ≥2 h after / ≥30 min before food. Route is chosen by target — oral capsule for gut, subcutaneous for systemic inflammation, topical for wounds/skin.
• KLOW blend convention: the common commercial vial runs roughly a 5:1:1:1 ratio: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg per 80 mg total — independently described by a practitioner as the “claw blend” and matching a vendor’s 80 mg blend (COA shows GHK-Cu 55.45 mg of that). Subcutaneous, cycled 4–6 weeks on with time off (up to ~12 weeks for more severe cases).
• Reconstitution: total mg ÷ mL of BAC water = mg/mL; draw your target dose on a U-100 insulin syringe.
• Trade-off: KLOW fixes all four ratios, so you can’t titrate KPV (or any component) independently the way you could buying them separately. The upside is one verified vial covering four signals.
• Delivery note: KPV barely crosses intact human skin without microneedling or iontophoresis, which is part of why the injectable route exists — and why Kirkland’s group sells an oral KPV supplement (3-amino-acid peptides survive digestion well enough to be orally active). In the KLOW blend, KPV rides the subcutaneous route with the others.

The one operational rule that’s easy to miss: don’t fight the peptide. If you’re running KLOW (or KPV) for an inflammatory target, the highest-leverage habit is to stop feeding the inflammation while KPV works: minimize alcohol, ultra-processed food, and heavy NSAID use, and support the gut lining with fiber/pectin-rich foods, kefir, collagen, and glutamine. This is the OHM whole-body move — the peptide is the accelerant, the foundation is what it accelerates; “you can’t peptide your way out of poor sleep, bad nutrition, or no training”. Don’t write “take KLOW” without “and here’s how not to defeat it.”

Expert disagreement worth knowing. One practitioner’s single-vial objection applies here too — he name-checks KPV specifically as something he’d keep separate from GHK-Cu rather than co-formulate. Against that: Kirkland confirms these blends hold up on HPLC over years of compounding (the real failures are specific pairs like retatrutide + NAD), and Dr. Jones independently builds and endorses the exact KLOW formula. The blend case is convenience and a fixed verified ratio across four signals; the separate-vial case is independent titration and avoiding cross-talk. Both are defensible — show both, let the evidence and Rick decide.

Side effects & management

No blend-level safety dataset, so this is assembled from components and user reports — generally mild:

• Injection-site reactions (redness, swelling, bruising, copper sting from GHK-Cu) are the most common reports. Rotate sites; dose GHK-Cu with food for GI comfort.
• KPV: no human safety dataset yet; its action is broadly immune-modulating, and long-term human consequences are simply not characterized — known unknown, not a known harm.
• BPC-157: theoretical VEGF/angiogenesis consideration; no animal carcinogenic signal.
• GHK-Cu copper load: avoid in Wilson’s disease and hemochromatosis; guides also flag pregnancy, under-18, and caution with active cancer.
• WADA: BPC-157 and TB-500 are prohibited for tested competitive athletes.

No serious adverse events appear in the indexable community reports for the stack — reassuring, not a formal safety profile. Cycling and conventional dosing is how users manage the unknowns.

Regulatory status

Not FDA-approved. No component is approved for human injection; GHK-Cu is approved only as a topical cosmetic; KPV is a Category 2 bulk substance (insufficient human safety data) and not approved for any indication. Injectable GHK-Cu, BPC-157, and KPV were moved to the FDA’s restricted compounding category in 2023, with a Pharmacy Compounding Advisory Committee review scheduled for July 23, 2026 [web, HealingMaps, Scientific American].

Joint and old-injury use — the case that keeps coming up (added 2026-08-25)

This article documents KLOW as a gut, recovery and skin blend. The use case readers actually arrive with is narrower and more stubborn: an old structural injury that never fully healed. The kind that was surgically repaired years ago, technically “fine,” and still dictates what the person will and will not do with their body a decade later. Nothing in the KLOW literature speaks to that directly — there is no trial on the four-way combination, as §3 says plainly — but the component logic is coherent, and the most detailed public anecdote to date is worth logging.

The component rationale, as run: KPV to damp inflammation, BPC-157 for tissue repair and vascular recovery, TB-500 to mobilize regenerative cells, GHK-Cu for matrix remodeling. Four mechanisms aimed at one healing problem rather than one mechanism aimed harder — which is the actual argument for a four-peptide blend over a single compound in a chronic, structurally-remodeled injury, and a better argument than the “more is more” framing the blends usually get sold on.

Nick Norwitz (MD/PhD) reports exactly this case: a knee injured at 17 as a competitive marathon runner, surgically repaired, never right afterward — scar tissue, inflammation, running and high-impact loading abandoned, a compression sleeve as standing management. Six weeks into injecting the four-peptide blend he reports squatting, jumping and lunging without the sleeve and without the familiar pain and inflammation. He frames it himself as an early, uncontrolled observation and had not resumed running.

How OHM should hold this. It is one person, six weeks, no control, no imaging, and a stack — the weakest tier of evidence there is, and it should never be presented as more than that. It is also a credentialed, specific, mechanistically-coherent account of the exact problem a large share of OHM readers are trying to solve, and pretending it does not exist is its own kind of dishonesty. Report it as an anecdote, name every limitation, let the reader weigh it. See GHK-Cu §3 for the same entry in the GHK-Cu article, and note the constraint that applies across the whole blend: no human injectable trial exists for GHK-Cu (verified against the ClinicalTrials.gov registry 2026-08-25 — all three registered GHK-Cu studies are topical or transdermal), and the BPC-157 and TB-500 human evidence bases are similarly thin. The case for KLOW on an old injury is mechanism plus practitioner and user experience. It is not a trials case, and OHM should not dress it as one.

Sources

• PubMed: four-way combination = 0 records (0019 corpus: review-only co-mentions, no primary combination study — this page’s honest framing). KPV — PMIDs 18061177, 18092346 (mouse colitis), 19909746 (nanoparticle), 28143741 (HA nanoparticle), 27458604 (PepT1/cancer model), 12750433, 11268348 (NF-κB/antimicrobial in vitro), 28343991 (transdermal permeation), 21222263, 37508552 (reviews). [0019 KPV corpus: 119 PubMed records — 3 HUMAN, 42 ANIMAL, 14 INVITRO; no human KPV-specific trial.] Other components — PMIDs 26236730, 18644225, 8227353 (GHK-Cu); 40756949 (BPC-157); 41229390 (Tβ4 RCT).
• Preprints (0019): Mendias 2026 musculoskeletal-peptide review covering BPC-157/TB-500/GHK-Cu + 7 others, DOI 10.20944/preprints202512.1011.v3; Mendias-group 2026 gray-market peptide purity study (6,441 samples / 14 compounds incl. three of KLOW’s four ingredients).
• Web: Dr. Dan Wool KPV; PeptideJournal KPV profile; HealingMaps KPV (July 23 2026 FDA review); Revolution Health KPV; Scientific American “The Science Behind the Peptide Craze” (Apr 2026).- Web (2026-06 verification): Dalmasso 2008 Gastroenterology “PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation” (gastrojournal.org / PMC2431115) — confirms PepT1-mediated, nanomolar NF-κB/MAPK suppression, oral KPV reduces DSS/TNBS colitis. Components: BPC-157 · TB-500 · GHK-Cu (+ KPV, no standalone page yet). Related blend: GLOW (KLOW minus KPV).